Coinfection of Schistosoma species with Hepatitis B or Hepatitis C Viruses

Rutgers University has made this article freely available. Please share how this access benefits you. Your story matters. [https://rucore.libraries.rutgers.edu/rutgers-lib/49601/story/]

This work is an ACCEPTED MANUSCRIPT (AM)

This is the author's manuscript for a work that has been accepted for publication. Changes resulting from the publishing process, such as copyediting, final layout, and pagination, may not be reflected in this document. The publisher takes permanent responsibility for the work. Content and layout follow publisher's submission requirements.

Citation for this version and the definitive version are shown below.

Citation to Publisher


Citation to this Version:


© 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/

Terms of Use: Copyright for scholarly resources published in RUcore is retained by the copyright holder. By virtue of its appearance in this open access medium, you are free to use this resource, with proper attribution, in educational and other non-commercial settings. Other uses, such as reproduction or republication, may require the permission of the copyright holder.

Article begins on next page

SOAR is a service of RUcore, the Rutgers University Community Repository
RUcore is developed and maintained by Rutgers University Libraries
Table 1.3.4 Studies Conducted on Subjects with Acute or Chronic Hepatitis from Hepatitis B Virus.

<table>
<thead>
<tr>
<th>No.</th>
<th>Reference</th>
<th>Location (Years)</th>
<th>Study Design (Objective) and Study Population</th>
<th>Exclusion Criteria</th>
<th>Diagnosis of Disease</th>
<th>Findings on Coinfection</th>
</tr>
</thead>
</table>
| 1   | Andrade et al. 2014 | Federal University, Minas Gerais, Brazil (1998-2012) | Cross-sectional (prevalence, severity, risk factors) 
Subject: 406 adults with chronic HBV (HBsAg+ for > 6 months), median age 45 years, 64% male | No HCV, no other liver diseases; 
Note: HDV not tested as population came from non-endemic Brazilian area | HBV: HBsAg, HBeAg, HBeAb, HBV-DNA; Chronic HBV: HBsAg+ >6 mo; Replicative HBV: HBV DNA>=2,000 IU/m; Sch(sm): patient history, stool/rectal mucosa; SPF: ultrasound, liver biopsy | Coinfection with Sch was detected in 31% of patients with chronic HBV, of which 61% had replicative CHB and 39% were inactive HBV carriers; Among the coinfected, 70% had SPF; After controlling for alcohol consumption and HBV load, coinfected patients had significantly more severe liver fibrosis than HBV mono infected patients (44% vs. 26%); Patients with replicative CHB and SPF had more advanced fibrosis and severe inflammation compared with patients wo/SPF (80% vs 44%). |
| 2   | Nooman et al. 1977 | Assiut University Hospital and Assiut University Fever Hospital, Egypt (n.d.) | Cohort (comparative, risk factors, disease progression, severity) Patient groups: 111 patients with acute viral hepatitis and 93 patients with acute viral hepatitis w/Sch, aged 2-66 years, 64% male | n.a. | HBV: HBsAg; Sch(Sm,Sh): stool, urine, rectal snip; SHF: liver biopsy | HbsAg+ occurred slightly more often among Sch- AVH patients than it did among those who were Sch+ (47% vs. 56%); Over the followup period, coinfected patients had a greater duration of antigenaemia (mean 95 days ± 143 days) than those with HBsAg+ alone (mean 36 days ± 61 days), and was not affected by specific Sch treatment; Sch infection may prolong the retention of HBsAg after an acute attack. |
Table 1.3.4 Studies Conducted on Subjects with Acute or Chronic Hepatitis from Hepatitis B Virus.

<table>
<thead>
<tr>
<th>Study</th>
<th>Institution</th>
<th>Study Design</th>
<th>Subjects</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Gaffar et al. 1991</td>
<td>Shebin El Kom Fever Hospital, Egypt (1983-1985)</td>
<td>Cohort (severity, disease progression, risk factors)</td>
<td>Patients: 144 acute viral hepatitis patients, predominately rural, n.o.s.;</td>
<td>No Wilson's disease, hemolysis or cholestasis; No patients had HAV</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Note: Patients were seen on at 3 of 4 scheduled visits over 1 year</td>
<td>Overall, 64% had acute HBV and 62% were Sch+; Coinfection of Sch w/acute HBV+ was detected in 37% of patients, of which 25% were tri-infected with HDV; 1 year after admission to hospital, the HbsAg carrier rate was nearly 4 fold higher in those with Sch, with greater splenomegaly, more persistent and greater liver function abnormalities, more severe histological findings on liver biopsies, and higher mortality than those with acute HBV infection alone; Splenomegaly increased from 40% to 69% in coinfected over 12 months, compared with 11% to 20% in those with HBV alone; Both male sex and coinfection were associated with the prolonged HBSAg carrier state.</td>
</tr>
<tr>
<td>4 El-Hawy et al. 1993</td>
<td>Al-Azhar University Hospital, Egypt (1991-1992)</td>
<td>Case Series/Case Control (severity, risk factors)</td>
<td>Cases: 54 patients with chronic active hepatitis (CAH), aged 18-43 years, 69% male; Controls: 20 healthy subjects matched by age and sex (used in some analyses only); Note: all patients had HBsAg in hepatocytes; This study also tested for antibodies to HDV; 28% of patients were tri-infected with HBV, HDV and Schistosomiasis</td>
<td>HBV: HBsAg, HBCa, HBeAg, HBcAg; Sch(Sm,Sh): stool, urine, sigmoidoscopy; CAH: Liver biopsy; Note: all patients had HBsAg in hepatocytes; This study also tested for antibodies to HDV; 28% of patients were tri-infected with HBV, HDV and Schistosomiasis Serological markers among the 54 patients with CAH indicated that 67% were HBsAg+ and 28% HBsAg+ w/HDV; Coinfection with Sch was also fairly common (39%), with 32% Sch+ w/HBsAg+: Similar proportions of Sch were found among those with HBsAg+ or HBsAg+ w/HDV+ serological markers (48% vs. 47%), which was greater than that observed among controls (22%); Tri-infected patients (n=7) showed the greatest altered liver profile, with greater advanced liver disease, and had the highest mortality.</td>
</tr>
</tbody>
</table>